Gen Z workers are coming for the workforce whether you like it or not. This Houston business leader likes it — and shares why you should embrace these future generation of employees too. Photo via Getty Images

My experience hiring Gen Z has been extremely positive — though many employers have complaints about that generation.

In my experience, employers say Gen Z folks:

  1. Don’t have a work ethic
  2. Lack discipline
  3. Demand instant gratification
  4. Think they deserve attention just for being alive (because they have always had attention)
  5. Think they are better and smarter than their bosses
  6. Are happy to tell their bosses what is wrong with them
  7. Are overly sensitive and easily offended
  8. Demand freedom and “personal space”
  9. Won’t bother learning something they don’t think is important

In a very recent ResumeBuilder survey of more than 1,300 managers, 74 percent of respondents said they find Gen Z more difficult to work with than other generations. Of those, 12 percent said they had to fire a young worker within their first week on the job.

That’s a damning list of negative attributes, especially to mature generations who were raised to believe the world didn’t owe them a living. Many older hiring authorities expect their team to behave the way they did 30 or so years ago. Namely, that new people at the firm should work hard to demonstrate that the company is their most important priority and, in return, they can patiently earn promotions over time after having proved themselves.

My firm manages over half a billion dollars for a short list of individuals and institutions. Every client is extremely valuable to us. Why would we ever hire Gen Z employees who, according to all the negative descriptions above, might endanger our client relationships?

Truth be told, I haven’t found the negative stereotypes about Gen Z to be accurate. I actually like hiring them and helping them integrate with our current mix of employees.

I think Gen Z employees expect their leaders to give deeply of themselves because they want the same thing we all want: to work for a company with a meaningful mission statement that gives a sense of purpose and significance to its employees. They want to see values, not the values hanging on the wall as a beautiful display, but the kind that actually set the tone for daily service, team commitment, and performance. They are sharp enough to immediately recognize when a company does not practice what it preaches. If they are disillusioned, they’re not going to perform as well and maybe they’ll leave.

Gen Z, like all of us, is hungry to learn what they need to know, especially when the knowledge will truly help them make an impact at their job. They are looking for valuable guidance instead of the “party line,” and they respond well to honesty and integrity (also known today as transparency and authenticity).

If a smart, talented professional at the start of a promising career is disillusioned with your company, you should first ask yourself if you’re using them as a disposable resource, or if you’ve truly invested in them by promoting a company culture that is honest, open, and transparent.

Problems with Gen Z in the workplace may be more complex than just pointing a finger at the youngest employees while waving a list of stereotypes. For example, Gen Z employees are said to be overly sensitive and easily offended. Maybe that’s another way of saying they expect to give something valuable for the salary they earn, and they (like all of us) want to see and understand a clear path to advancement. “Do it because I said so,” doesn’t work because they’ve seen so many of their parents give years of effort to a system that downsized them without warning.

When a company’s leaders fire an entire department over the weekend, they may have helped improve the bottom line, but they also have shaped the way that incoming generations look at the workplace. Because up-and-coming professionals have seen the bosses of today reducing benefits and eliminating pensions, they are logically asking for more genuine attention and commitment from their leaders.

On our team, we find that a great first step to changing that cycle is to listen to Gen Z hires, not because of their age, but because all members of the team have a stake. When our leaders’ actions show a genuine encouragement to share opinions and insight, it’s not just Gen Z workers who flourish. When the leaders of a firm model integrity in an environment that offers a clear path forward in their employees’ careers, all members of the team, regardless of generation, will feel the loyalty that is the natural response to respect and dedication.

There will always be other jobs at other companies offering various levels of pay. When you provide your team with a meaningful place in a growing organization that comports itself in a way that makes the members proud to be associated with it, then suddenly a few more dollars of salary at another workplace doesn’t look as attractive.

I just hired another member of Gen Z, and I’m looking forward to working with this young employee who will undoubtedly have a fresh perspective and hard questions. You might enjoy a similar experience if you stop thinking of them as a stereotype and instead honestly exchange ideas. Let your daily discipline and commitment to high ideals give them an example that they can look up to and admire.

I’m reminded of this quote from Antoine de Saint-Exupéry: “If you want to build a ship, don’t drum up the men to gather wood, divide the work, and give orders. Instead, teach them to yearn for the vast and endless sea.”

Gen Z offers a chance for all of us to improve how we do business. Take advantage of it and teach them well.

------

Christopher Manske is a Certified Financial Planner and president of Houston-based Manske Wealth Management. An author, his next book, Outsmart the Money Magicians, is expected this fall with McGraw Hill.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.